The federal government set a clear deadline. Congress instructed the U.S. Food and Drug Administration (FDA) to publish long-awaited guidance on hemp-derived cannabinoids — including an official list of cannabinoids and a definition clarifying what counts as a “container” when calculating THC serving limits. The date came and went. The guidance did not.
The deadline, mandated through a federal spending bill, was intended to bring structure and clarity to an industry that has been operating in a gray area for years. With tighter federal hemp rules on the horizon — including stricter total THC limits — businesses were counting on the agency’s definitions to understand how products will be evaluated and regulated.
Without that clarity, manufacturers, retailers, and state regulators are left guessing. Industry stakeholders say the absence of guidance makes it nearly impossible to prepare for compliance, particularly as implementation deadlines approach later this year. Questions surrounding serving sizes, packaging classifications, and which cannabinoids fall within federal limits remain unanswered.
The FDA, overseen by the U.S. Department of Health and Human Services, had indicated it was working on the required materials. However, as of the deadline, nothing has been formally issued.
The missed target adds another layer of uncertainty to an already complicated hemp marketplace — and it increases pressure on lawmakers who may now face calls to delay enforcement timelines until regulators catch up.
For an industry built on evolving chemistry and shifting policy, one thing remains consistent: when Washington sets a cannabis clock, it doesn’t always mean someone winds it.
Dabbin-Dad Newsroom
